Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here


Trump Names Dr. Norman Sharpless to Serve as Director of National Cancer Institute

Dr. Norman “Ned” Sharpless

Washington, DC, June 19, 2017Science reports that President Donald Trump on June 9 announced his intention to appoint Norman “Ned” Sharpless, M.D., to be the next director of the National Cancer Institute (NCI) in Bethesda, Maryland.

Dr. Sharpless would succeed Harold Varmus as the head of NCI.

Sharpless, 50, is a physician and currently director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill.  He also holds an academic appointment at the university’s school of medicine. Continue reading

Congress Boosts Research Funding in Cancer, Alzheimer’s, Precision Medicine, BRAIN Initiative and ‘Superbugs’

Washington, DC, May 2, 2017 — Ariana Eunjung Cha reports in The Washington Post that Congress unveiled a bipartisan budget late Sunday that contains a number of welcome surprises for researchers who had been panicking since March, when President Trump proposed deep funding cuts for science and health.

Under the deal, the National Institutes of Health will get a $2 billion boost in fiscal year 2017, as it did the previous year.

Trump had proposed cutting the NIH budget by about one-fifth, or $6 billion, in a draft 2018 budget.

Here are some of the big research winners: Continue reading

American Cancer Society and National Cancer Institute Publish Annual Report to the Nation: Cancer Death Rates Continue to Decline

Bethesda, MD, April 11, 2017 — Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975 – 2014.

The Report to the Nation is released each year in a collaborative effort by the American Cancer Society; the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), both parts of the Department of Health and Human Services; and the North American Association of Central Cancer Registries (NAACCR).

The latest report, which was published on March 31, finds that death rates during the period 2010-2014 decreased for 11 of the 16 most common types of cancer in men and for 13 of the 18 most common types of cancer in women, including lung, colorectal, female breast, and prostate cancers. Continue reading

National Cancer Institute: Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers

Bethesda, MD, March 15, 2017Douglas R. Lowy, M.D., Acting Director, National Cancer Institute last month wrote:

The 21st Century Cures Act, which was signed into law in December 2016, authorizes $1.8 billion over 7 years to fund the Beau Biden Cancer Moonshot℠, $300 million of which is available in Fiscal Year 2017.

These funds enable NCI to begin, this fiscal year, implementing cancer research initiatives that align with the goals outlined in last fall’s report from the Cancer Moonshot Blue Ribbon Panel (BRP) and to rapidly build on progress that NCI and its many research partners have achieved over the years. Continue reading

Rutgers Cancer Institute of NJ Resident Receives $1.8M Grant to Explore Chronic Stress Role in Cancer Development

Wenwei Hu, Ph.D.

Wenwei Hu, Ph.D.

New Brunswick, NJ, January 28, 2017 — A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, Ph.D., will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors – p53.

The aim is to explore how chronic stress impacts cancer development, especially when cancers containing a mutation in p53, and identify molecular targets that would disrupt the effect of chronic stress on cancer development.

The p53 protein plays a central role in preventing cancer development, as loss of its tumor suppressor function has been shown to contribute greatly to cancer development. Continue reading

FDA Establishes the Oncology Center of Excellence; Dr. Richard Pazdur to Serve as Director

FDA blueWashington, DC, January 23, 2017 — Outgoing Food and Drug Administration (FDA) Commissioner Dr. Robert Califf on January 19 announced that the agency was founding the Oncology Center of Excellence (OCE) and that Dr. Richard Pazdur would serve its inaugural director.

Califf said this will make oncology the first disease area to have a coordinated clinical review of drugs, biologics and devices across the agency’s three medical product centers. Continue reading

Event: HINJ to Co-Sponsor Rutgers-Industry Cancer Research Symposium on January 24

Rutgers CINJ LogoNew Brunswick, NJ, January 18, 2017 — The HealthCare Institute of New Jersey (HINJ) is pleased to co-sponsor a Rutgers-Industry Cancer Symposium that will be presented on Tuesday, January 24 from 4:00 to 6:00 p.m. in Auditorium A and B at the Rutgers Cancer Institute of New Jersey at 195 Little Albany Street, New Brunswick.

This series is designed to foster collaboration and networking between Rutgers faculty and strategic industry partners.

At the January 24 symposium, Rutgers researchers will present an update on clinical investigations.

In addition, Incyte Corporation will present an update on drugs in its pipeline.

Registration is not required.  For the event flyer, click here.

Opinion: Vice President Joe Biden Won’t Keep Quiet Against Cancer

Biden and ObamaWashington, DC, January 14, 2017Robert Goldberg, Vice President, Center for Medicine in the Public Interest, writes in The Hill:

Vice President Joe Biden won’t be playing a lot of golf after he leaves office. Instead, he will continue to take his whacks against cancer through a new non-profit that will carry on the mission of the Cancer Moonshot program he chaired.

A Washington Post article reports that the new organization will continue to advance the Moonshot goals, “including the need to knock down “silos” in cancer research and share research data and medical records more widely, boosting participation in clinical trials, and finding new ways to improve treatment provided by community oncologists. Continue reading

National Cancer Institute and Drug Companies Aim to Speed Up Clinical Trials

nih-national-cancer-instituteBethesda, MD, January 13, 2017 — The National Cancer Institute (NCI) on January 11 launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.

The NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.

The NCI Formulary is a public-private partnership between NCI, part of the National Institutes of Health, and pharmaceutical and biotechnology companies. Continue reading

VP Biden Outlines Steps to Pursue Post-Obama ‘Cancer Moonshot’

Vice President Joe Biden

Vice President Joe Biden

Washington, DC, January 11, 2017 — Vice President Joe Biden is outlining how he intends to pursue his “cancer moonshot” agenda after the end of the Obama administration, the Associated Press reports.

Biden says in a San Francisco speech that he will be starting an organization that may be called the Biden Cancer Initiative to make progress in changing the way the nation conducts cancer research and development and providing care to those with the disease. Continue reading